Biogen Idec and Elan won an important endorsement for Tysabri with a recommendation from Britain's cost-effectiveness watchdog--the National Institute for Health and Clinical Excellence--that the drug be made available to patients with the most severe form of the disease. Tysabri has been making a steady comeback [1] since the therapy was derailed in early '05 after patients taking the drug developed a rare brain disease. Regulators ushered it back onto the market after adding some restrictive guidelines on its use after a large contingent of MS patients demanded access to the therapy.

- check out the release [2]
- read the report [3] from the Irish Times

Related Articles:
FDA committee backs Tysabri for Crohn's [4]
After reintroduction, Tysabri builds patient base [5]
FDA allows Tysabri back on market [6]